New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:16 EDTJAZZ, PUBGY, SKUL, POST, AKRX, OMC, AAPL, UBNT, CSC, POn The Fly: Closing Wrap
Stocks on Wall Street were higher in a choppy session that saw the averages spend time on either side of the flatline before gaining ground in the last hour of trade to close near session highs. With today's close, the S&P 500 and Nasdaq finished the week with losses, while the Dow gained about 0.4% to close at new all-time closing high. ECONOMIC EVENTS: In the U.S., wholesale inventories were up 1.1% in March, which was above the 0.5% forecast, while wholesale sales rose 1.4% in the month. The JOLTS report showed job openings fell 111K in March to 4.01M. COMPANY NEWS: Apple (AAPL) was in-focus after the Financial Times said last night that the iPhone and iPad maker is in talks to acquire Beats Electronics for $3.2B. Following the report of Apple's interest in the headphone maker co-founded by rapper and record producer Dr. Dre, shares of another audio equipment maker, Skullcandy (SKUL), gained 32c, or 4.66%, to $7.18. Pandora (P), which like Beats offers a music streaming service, was up 42c, or 1.89%, to $22.62... Shares of Omnicom (OMC) rose $1.46, or 2.21%, to $67.66 after the company and its advertising peer Publicis Groupe (PUBGY) terminated their proposed merger of equals, citing "difficulties in completing the transaction within a reasonable timeframe." MAJOR MOVERS: Among the notable gainers was CSC (CSC), up $4.35, or 7.49%, to $62.39 after reporting a mixed fourth quarter report but raising its dividend 15% and announcing a new $1.5B share repurchase program. Also higher was Akorn (AKRX), which gained $1.12, or 4.53%, to $25.82 after announcing an agreement to acquire VersaPharm for $440M in a deal the company expects to add $90M-$100M in annual revenue and 10c-12c per share in earnings. Among the noteworthy losers was Jazz Pharmaceuticals (JAZZ), down $4.24, or 3.17%, to $129.45 after the company's first quarter profit and revenue fell short of expectations. Analysts at Piper Jaffray, however, said Jazz's growth story is still "very much intact." Also lower following their quarterly reports were shares of Ubiquiti Networks (UBNT), down $9.99, or 24.15%, to $31.38 and Post Holdings (POST), down $4.05, or 7.78%, to $48.03. INDEXES: The Dow gained 32.37, or 0.20%, to 16,583.34, the S&P 500 was up 2.85, or 0.15%, to 1,878.48, the Nasdaq was up 20.37, or 0.50%, to 4,071.87.
News For AAPL;SKUL;P;OMC;PUBGY;CSC;AKRX;JAZZ;UBNT;POST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 21, 2015
11:57 EDTAKRXAkorn rises, Perrigo slips after Teva makes long-rumored Mylan bid
The shares of drugmaker Akorn (AKRX) are rising after Israeli pharmaceutical company Teva (TEVA) earlier today made a takeover bid for another company in the space, generic drugmaker Mylan (MYL). WHAT'S NEW: Teva announced an $82 per share takeover bid for generic drug maker Mylan earlier today. The latter company said that Teva's takeover offer is a more attractive option for it than acquiring another generic drug maker, Perrigo (PRGO). On April 8, Mylan made a $205 per share takeover offer for Perrigo. Teva's bid comes less than a week after Mylan Chairman Robert Coury said that rumors of potential interest from Teva had been "circulating for some time," but that such a combination was "without sound industrial logic or cultural fit" and would be unlikely to receive antitrust regulatory clearances. ANALYST OPINION: In a note to investors on April 15, RBC Capital analyst Randall Stanicky wrote that Perrigo may have been engaging other companies in talks after Mylan came public with its takeover offer. Stanicky said he saw no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. The analyst added that Acorn is well-positioned as a derivative takeover target following Mylan's offer for Perrigo, noting Acorn's strong growth and high tax rate. In a note to investors yesterday, Citigroup said it believed a potential takeover of Mylan by Teva would have to be friendly after its legal due diligence indicated Mylan's poison pill "presents a legitimate roadblock" to a potential hostile takeover. Citi estimated an $80 per share bid for Mylan would be 25%-35% accretive from 2016 onward for Teva while a $90 per share bid would be 20%-30% accretive. The firm added that it believes it is likely that Mylan received resistance from shareholders since the announcement of its proposed acquisition of Perrigo. PRICE ACTION: In late morning trading, Akorn rose 2.2% to $55.85, Perrigo dropped 2.4% to $193.24, Mylan jumped 9.3% to $74.39, and Teva rose 2.1% to $64.64.
11:00 EDTAAPLStocks with call strike movement; AMZN AAPL
Subscribe for More Information
10:34 EDTAAPLCorning sapphire glass rumored to be in new Apple iPhone, PatentlyApple says
Subscribe for More Information
09:37 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:29 EDTUBNTUbiquiti Networks results likely to beat expectations, says Bernstein
Subscribe for More Information
08:20 EDTAAPLOrbitz app now customized for Apple Watch
Subscribe for More Information
07:08 EDTOMCOmnicom reports Q1 EPS 83c, consensus 82c
Reports Q1 revenue $3.47B, consensus $3.48B. Reports Q1 Domestic revenue $1.96B. Reports Q1 International revenue $1.51B. Reports Q1 organic revenue increased 4.8% in North America, 9.3% in the United Kingdom, 2.7% in the Euro Markets and Other Europe, 6.7% in Asia Pacific, 3.4% in Latin America and 10.6% in Africa/Middle East, when compared to the same quarter of 2014.
06:18 EDTAAPLCitigroup unenthused with IBM mix, still prefers Apple
Subscribe for More Information
05:58 EDTAAPLReport: AU Optronics to supply Apple with iPhone panels, DigiTimes says
Subscribe for More Information
April 20, 2015
16:01 EDTAAPLOptions Update; April 20, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 21.52. Option volume leaders: AAPL VZ PBR TWTR TSLA TWTR NFLX MCP FB AMZN AA C according to Track Data.
15:37 EDTOMCNotable companies reporting before tomorrow's open
Subscribe for More Information
14:32 EDTJAZZPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
12:02 EDTPPandora April weekly volatility elevated into Q1 and growth outlook
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:42 EDTAAPLApple May weekly volatility elevated into Q2 and outlook
Subscribe for More Information
08:18 EDTAAPLApple Q2 EPS estimate raised above consensus at Pacific Crest
Pacific Crest raised its Q2 EPS estimate for Apple to $2.17 from $2.15, putting it above the consensus estimate of $2.14. The firm raised its Q2 estimate based on an increase in its iPhone unit outlook, and raised its fiscal 2015 and fiscal 2016 EPS estimates for the company based on higher iPhone and Apple Watch estimates. Nonetheless the firm expects the company to face growth challenges in fiscal 2016, and it keeps a Sector Weight rating on the shares.
07:30 EDTAAPLApple Q2 results likely to beat expectations, says Wells Fargo
Subscribe for More Information
06:18 EDTAAPLAnalyst sees Apple Watch as company's 'most profitable product ever,' BI reports
Subscribe for More Information
05:44 EDTAAPLApple cuts orders to upstream partners to reduce risks, DigiTimes reports
Subscribe for More Information
05:22 EDTAAPLBooking.com launches first booking travel app for Apple Watch
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use